- Home
- ANIX vs GDL Comparison
ANIX vs GDL Comparison
Compare ANIX & GDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- GDL
- Stock Information
- Founded
- ANIX 1982
- GDL 2006
- Country
- ANIX United States
- GDL United States
- Employees
- ANIX N/A
- GDL N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- GDL Investment Managers
- Sector
- ANIX Health Care
- GDL Finance
- Exchange
- ANIX Nasdaq
- GDL Nasdaq
- Market Cap
- ANIX 95.7M
- GDL 93.3M
- IPO Year
- ANIX 1987
- GDL N/A
- Fundamental
- Price
- ANIX $2.94
- GDL $8.62
- Analyst Decision
- ANIX Strong Buy
- GDL
- Analyst Count
- ANIX 3
- GDL 0
- Target Price
- ANIX $9.00
- GDL N/A
- AVG Volume (30 Days)
- ANIX 64.6K
- GDL 11.2K
- Earning Date
- ANIX 09-10-2025
- GDL 01-01-0001
- Dividend Yield
- ANIX N/A
- GDL 6.02%
- EPS Growth
- ANIX N/A
- GDL N/A
- EPS
- ANIX N/A
- GDL N/A
- Revenue
- ANIX N/A
- GDL N/A
- Revenue This Year
- ANIX N/A
- GDL N/A
- Revenue Next Year
- ANIX N/A
- GDL N/A
- P/E Ratio
- ANIX N/A
- GDL N/A
- Revenue Growth
- ANIX N/A
- GDL N/A
- 52 Week Low
- ANIX $2.07
- GDL $7.65
- 52 Week High
- ANIX $4.20
- GDL $8.13
- Technical
- Relative Strength Index (RSI)
- ANIX 43.29
- GDL 67.58
- Support Level
- ANIX $2.93
- GDL $8.56
- Resistance Level
- ANIX $3.09
- GDL $8.64
- Average True Range (ATR)
- ANIX 0.11
- GDL 0.04
- MACD
- ANIX 0.00
- GDL 0.01
- Stochastic Oscillator
- ANIX 1.85
- GDL 88.09
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.